Merit Medical posts Q3 revenue growth, raises full‑year EPS guidance and completes Solo Pace acquisition
Merit Medical Systems reported third‑quarter 2026 revenue of $416.2 million, up 8.4% year‑over‑year on a reported basis, and non‑GAAP earnings per share of $1.12, a 21.7% increase. GAAP operating margin rose to 14.1% from 11.1% a year earlier. The company lifted its full‑year 2026 non‑GAAP EPS guidance to $4.33‑$4.37 per share and disclosed the $45 million purchase of Solo Pace, adding to its cardiac‑therapies platform. Gross margin fell 81 basis points to 52.8% on a reported basis.
Why it matters
The higher EPS guidance signals stronger profitability expectations for the year, which could support the stock price (the company expects non‑GAAP EPS growth of roughly 13‑14%). The Solo Pace acquisition expands Merit’s product offering in the growing TAVR market, potentially driving future revenue growth.
Key facts
- 1Q3 2026 revenue was $416.2 million, up 8.4% year‑over‑year on a reported basis. investing.com
- 2Non‑GAAP EPS for the quarter was $1.12, up 21.7% year‑over‑year on an adjusted basis. investing.com
- 3GAAP operating margin expanded to 14.1% in Q3, from 11.1% in the prior‑year quarter. investing.com
- 4Full‑year 2026 non‑GAAP EPS guidance was raised to a range of $4.33‑$4.37 per share. investing.com
- 5Gross margin declined 81 basis points year‑over‑year to 52.8% on a reported basis. finance.yahoo.com
- 6Merit Medical completed the acquisition of Solo Pace for $45 million. finance.yahoo.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.